Nj State Employees Deferred Compensation Plan Arrowhead Pharmaceuticals, Inc. Transaction History
Nj State Employees Deferred Compensation Plan
- $824 Million
- Q3 2024
A detailed history of Nj State Employees Deferred Compensation Plan transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Nj State Employees Deferred Compensation Plan holds 10,500 shares of ARWR stock, worth $204,225. This represents 0.02% of its overall portfolio holdings.
Number of Shares
10,500
Previous 10,500
-0.0%
Holding current value
$204,225
Previous $272,000
25.37%
% of portfolio
0.02%
Previous 0.03%
Shares
1 transactions
Others Institutions Holding ARWR
# of Institutions
294Shares Held
90.8MCall Options Held
155KPut Options Held
426K-
Black Rock Inc. New York, NY15.7MShares$305 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$238 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.89MShares$173 Million2.59% of portfolio
-
State Street Corp Boston, MA6.35MShares$124 Million0.01% of portfolio
-
Slate Path Capital LP New York, NY4.89MShares$95 Million1.49% of portfolio
About ARROWHEAD PHARMACEUTICALS, INC.
- Ticker ARWR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 105,849,000
- Market Cap $2.06B
- Description
- Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...